البروفيسور سركان أوزاكباش

<ul> <li><strong>Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)</strong> <br>Authors: Şen S., KÜRTÜNCÜ M., Demir S., GÜNDÜZ T., Demirel E., Tütüncü M., et al. <br>Citations: Unknown, Year: 2025 </li> <li><strong>Effect of the synchronized telerehabilitation-based upper extremity training program on hand-arm functions in people with multiple sclerosis</strong> <br>Authors: Dastan S., ERTEKİN Ö., Özdoğar A. T., Kahraman T., Baba C., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2025 </li> <li><strong>Effect of Telerehabilitation-Based Motor Imagery Training on Pain and Related Factors in People With Multiple Sclerosis: Randomized Controlled Pilot Trial</strong> <br>Authors: Karakas H., Kahraman T., Özdoğar A. T., Baba C., Ozakbas S. <br>Citations: Unknown, Year: 2025 </li> <li><strong>First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis</strong> <br>Authors: Toscano S., Spelman T., Ozakbas S., Alroughani R., Chisari C. G., Lo Fermo S., et al. <br>Citations: Unknown, Year: 2025 </li> <li><strong>Prevalence and Magnitude of Perceived Dual-Task Difficulties in People With Multiple Sclerosis: An International Study</strong> <br>Authors: Abasıyanık Z., Pedullà L., Kahraman T., Soler B., Santoyo-Medina C., Tacchino A., et al. <br>Citations: Unknown, Year: 2025 </li> <li><strong>The relationship between work difficulties and physical disability, cognitive and social cognitive impairment and subcortical gray matter atrophy in persons with multiple sclerosis</strong> <br>Authors: Aslan T., Özdoğar A. T., Sagici O., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis</strong> <br>Authors: Roos I., Sharmin S., Malpas C., ÖZAKBAŞ S., Lechner-Scott J., Hodgkinson S., et al. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Investigation of the Relationship Between Coping With the Disease and Afecting Cognitive, Physical, and Psychosocial Factors in People with Multiple Sclerosis</strong> <br>Authors: Sagici O., ÖZDOĞAR A. T., Aslan T., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey</strong> <br>Authors: ÇELİK M., Baba C., IRMAK Ç., Özbakbaş S., AVKAN OĞUZ V. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry</strong> <br>Authors: Signori A., Ponzano M., Kalincik T., ÖZAKBAŞ S., Horakova D., Havrdova E. K., et al. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study</strong> <br>Authors: Spelman T., Simoneau G., Hyde R., Kuhelj R., Alroughani R., Ozakbas S., et al. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Predictors of relapse severity in multiple sclerosis</strong> <br>Authors: Baba C., Abasiyanik Z., Simsek Y., Ozdogar A. T., Sagici O., Ozakbas S. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Cognition as a parameter in monitoring the effect of multiple sclerosis relapse treatment: A prospective controlled study</strong> <br>Authors: Piri Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al. <br>Citations: Unknown, Year: 2024 </li> <li><strong>What might the COVID-19 pandemic in regard to people with neuromyelitis optica spectrum disorder teach us regarding the future?</strong> <br>Authors: Baba C., Yavas I., SAMADZADE U., ÖZDOĞAR A. T., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study</strong> <br>Authors: Ozakbas S., Baba C., Yavas I., SAMADZADE U., ÖZDOĞAR A. T. <br>Citations: Unknown, Year: 2024 </li> <li><strong>The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study</strong> <br>Authors: Levitz D., Chao Foong Y., Sanfilippo P., Spelman T., Rath L., Roldan A., et al. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Investigating the relationship of theory of mind and empathy with neuroimaging, neuropsychological, and neuropsychiatric data in persons with multiple sclerosis</strong> <br>Authors: Aslan T., ÖZDOĞAR A. T., Sagici O., Yigit P., Zorlu N., BORA İ. E., et al. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies</strong> <br>Authors: Li Y., Saul A., Taylor B., Ponsonby A., Simpson-Yap S., Blizzard L., et al. <br>Citations: Unknown, Year: 2024 </li> <li><strong>Risk of secondary progressive multiple sclerosis after early worsening of disability</strong> <br>Authors: Dzau W., Sharmin S., Patti F., Izquierdo G., Eichau S., Prat A., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial</strong> <br>Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Dual-task difficulties as a risk factor for unemployment in people with multiple sclerosis</strong> <br>Authors: Kahraman T., Temiz H., Abasiyanik Z., Baba C., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2023 </li> <li><strong>The risk of secondary progressive multiple sclerosis is geographically determined but modifiable</strong> <br>Authors: Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sánchez M. M., ÖZAKBAŞ S., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment</strong> <br>Authors: Sen S., Tuncer A., Terzi M., BÜNÜL S. D., Ozen-Acar P., Altunrende B., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Feasibility of Telerehabilitation-Based Pelvic Floor Muscle Training for Urinary Incontinence in People With Multiple Sclerosis: A Randomized, Controlled, Assessor-Blinded Study</strong> <br>Authors: Yavas I., Kahraman T., Sagici O., Ozdogar A. T., Yigit P., Baba C., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Disability accrual in primary and secondary progressive multiple sclerosis.</strong> <br>Authors: Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis</strong> <br>Authors: Roos I., Hughes S., McDonnell G., Malpas C. B., Sharmin S., BOZ C., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry</strong> <br>Authors: Spelman T., ÖZAKBAŞ S., Alroughani R., Terzi M., Hodgkinson S., Laureys G., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation</strong> <br>Authors: Zhu C., Kalincik T., Horakova D., Zhou Z., Buzzard K., Skibina O., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis</strong> <br>Authors: Kalincik T., Sharmin S., Roos I., Freedman M. S., Atkins H., Burman J., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?</strong> <br>Authors: Tütüncü M., Demir S., Arslan G., Dinç Ö., Şen S., GÜNDÜZ T., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis</strong> <br>Authors: Daruwalla C., Shaygannejad V., ÖZAKBAŞ S., Havrdova E. K., Horakova D., Alroughani R., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis</strong> <br>Authors: BOZ C., ÖZAKBAŞ S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Narrative review based on fingolimod therapy in pediatric MS.</strong> <br>Authors: Piri Cinar B., Konuskan B., Anlar B., Ozakbas S. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Effects of prolonged walking on dual-task walking performance in persons with multiple sclerosis</strong> <br>Authors: Abasiyanik Z., Kahraman T., Veldkamp R., ERTEKİN Ö., Kalron A., ÖZAKBAŞ S., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Psychometric properties of three self-report questionnaires assessing dual-task difficulties in people with multiple sclerosis: A multicenter study within the RIMS network</strong> <br>Authors: Abasiyanik Z., Pedulla L., Kahraman T., D’Hooge M., Santoyo-Medina C., Soler B., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Association between work-related difficulties and dual-task ability in people with multiple sclerosis</strong> <br>Authors: Temiz H., Kahraman T., Abasiyanik Z., Baba C., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis</strong> <br>Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Comparative effectiveness in multiple sclerosis: A methodological comparison</strong> <br>Authors: Roos I., Diouf I., Sharmin S., Horakova D., Havrdova E. K., Patti F., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry</strong> <br>Authors: Spelman T., ÖZAKBAŞ S., Alroughani R., TERZİ M., Hodgkinson S., Laureys G., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trial.</strong> <br>Authors: Ozdogar A. T., Ertekin Ö., Kahraman T., Dastan S., Ozakbas S. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity</strong> <br>Authors: Spelman T., Horakova D., ÖZAKBAŞ S., Alroughani R., Onofrj M., Kalincik T., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network</strong> <br>Authors: Signori A., Lorscheider J., Vukusic S., Trojano M., Iaffaldano P., Hillert J., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>The Preference-Based Multiple Sclerosis Index: an assessment of its psychometric properties and translation into Turkish</strong> <br>Authors: Kahraman T., Ozdogar A. T., Abasiyanik Z., Sagici O., Baba C., Ertekin Ö., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis</strong> <br>Authors: Şen S., Arslan G., Tütüncü M., Demir S., Dinç Ö., GÜNDÜZ T., et al. <br>Citations: Unknown, Year: 2023 </li> <li><strong>Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry</strong> <br>Authors: Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., ÖZAKBAŞ S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis</strong> <br>Authors: Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., ÖZAKBAŞ S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.</strong> <br>Authors: Baba C., Ozcelik S., Kaya E., Samedzada U., Ozdogar A. T., Cevik S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.</strong> <br>Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis</strong> <br>Authors: Baba C., Ozdogar A. T., ÖZÇELİK S., KAYA E., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS</strong> <br>Authors: Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta</strong> <br>Authors: Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Factors related to restless leg syndrome in neuromyelitis optica spectrum disorder</strong> <br>Authors: Ozdogar A. T., KAYA E., Sagici O., Dastan S., Karakas H., Baba C., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Predictive ability of the original and short form of the activities-specific balance confidence scale and its individual items for falls in people with multiple sclerosis</strong> <br>Authors: Abasiyanik Z., Kahraman T., Baba C., Sagici O., ERTEKİN Ö., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.</strong> <br>Authors: Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location.</strong> <br>Authors: Olmez O., Baba C., Abasiyanik Z., Ozakbas S. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Confirmed disability progression as a marker of permanent disability in multiple sclerosis</strong> <br>Authors: Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Effects and safety of exergaming in persons with multiple sclerosis during corticosteroid treatment: a pilot study</strong> <br>Authors: Ozdogar A. T., Baba C., Kahraman T., Sagici O., Dastan S., Ertekin Ö., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Comparison of late-onset and early-onset people with multiple sclerosis based on cognitive and physical assessments</strong> <br>Authors: Ozakbas S., Kaya E., Ozdogar A. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Comparative Effectiveness and Persistence of Cladribine Tablets from GLIMPSE: Results from the MSBase Registry</strong> <br>Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Sustained attention during prolonged walking in persons with multiple sclerosis</strong> <br>Authors: Abasiyanik Z., Kahraman T., Veldkamp R., Ertekin Ö., Kalron A., Ozakbas S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study</strong> <br>Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment</strong> <br>Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar T., Sagici O., Baba C. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis</strong> <br>Authors: Lefort M., Sharmin S., Andersen J. B., Vukusic S., Casey R., Debouverie M., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort</strong> <br>Authors: ÖZAKBAŞ S., ÇİNAR B. P., Baba C., Kosehasanogullari G. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry</strong> <br>Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Restless legs syndrome and related factors in people with multiple sclerosis in Turkey</strong> <br>Authors: Özdoğar A. T., Ertekin Ö., Kahraman T., Baba C., Özakbaş S. <br>Citations: Unknown, Year: 2022 </li> <li><strong>The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?</strong> <br>Authors: Sen S., Tuncer A., ÖZAKBAŞ S., Uzunkopru C., Baba C., Demir S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies</strong> <br>Authors: Özakbaş S., Baba C., Doğan Y., Cevik S., Özçelik S., Kaya E. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Fatigue is associated with physical inactivity in people with multiple sclerosis despite different environmental backgrounds: Merging and comparing cohorts from Turkey and Israel</strong> <br>Authors: ÖZDOĞAR A. T., Kahraman T., ÖZAKBAŞ S., Achiron A., Kalron A. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic</strong> <br>Authors: Baba C., Yigit P., Dastan S., Hancer P., Sagici O., ÖZAKBAŞ S., et al. <br>Citations: Unknown, Year: 2022 </li> <li><strong>Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts</strong> <br>Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry</strong> <br>Authors: Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis</strong> <br>Authors: Simpson-Yap S., De Brouwer E., Kalincik T., Rijke N., Hillert J. A., Walton C., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018</strong> <br>Authors: Moradi N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., TERZİ M., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Effect of exergaming in persons with multiple sclerosis with restless legs syndrome: a randomized controlled trial</strong> <br>Authors: Ozdogar A. T., Ertekin O., Kahraman T., Aslan A. T., Dastan S., Ozakbas S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Comparatve effectveness of beta-nterferons and glatramer acetate on physcal and cogntve functons: 6-month follow-up study</strong> <br>Authors: Ozakbas S., Aslan T., Abasiyanik Z., Ozdogar A. T. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort</strong> <br>Authors: Sharmin S., Malpas C., Roos I., Diouf I., Alroughani R., Ozakbas S., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Comparative analysis of early treatment effectiveness of first-line disease-modifying therapies and fingolimod on cognitive functions in persons with multiple sclerosis</strong> <br>Authors: Yigit P., Sagici O., Abasiyanik Z., Baba C., Ozakbas S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>External validation of the MSBase model of individual treatment response (Crystal Ball 1.0)</strong> <br>Authors: Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Terzi M., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis</strong> <br>Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study</strong> <br>Authors: Butzkueven H., Spelman T., Ozakbas S., Boz C., Buzzard K., Skibina O., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Incidence and predisposing factors of COVID-19 in patients living with multiple sclerosis: Results from a prospective multiple sclerosis cohort</strong> <br>Authors: Ozakbas S., Berktas M., Aslan T., Baba C. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models</strong> <br>Authors: Diouf I., Malpas C., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Comparison of early treatment response of ocrelizumab in relapsing and progressive multiple sclerosis patients on the basis of cognitive functions</strong> <br>Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar A. T., Sagici O., Baba C. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis</strong> <br>Authors: Roos I., Sharmin S., Ozakbas S., Horakova D., Havrdova E. K., Boz C., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Relapse during the washout period predicts time to relapse after switching to cladribine</strong> <br>Authors: Zhong M., van der Walt A., Hodgkinson S., Izquierdo G., Eichau S., Kalincik T., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Cognition as a parameter that should not be ignored when evaluating the effect of relapse treatment: A prospective controlled study</strong> <br>Authors: Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Real-world experience with cladribine in the MSBase Registry</strong> <br>Authors: Butzkueven H., Spelman T., Hodgkinson S., Madueno S. E., Izquierdo G., Buzzard K., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis</strong> <br>Authors: Ozakbas S., Ozdogar A. T., Baba C., Ozcelik S., Kaya E. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Associations between smoking and walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis</strong> <br>Authors: Kahraman T., ÖZDOĞAR A. T., Abasiyanik Z., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Determinants of therapeutic lag in multiple sclerosis</strong> <br>Authors: Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Does the reason for the switch to fingolimod affect the treatment response?</strong> <br>Authors: Ozakbas S., Aslan T., Ozdogar A. T., Abasiyanik Z., Sagici O. <br>Citations: Unknown, Year: 2021 </li> <li><strong>A comparative study of the effects of yoga and clinical Pilates training on walking, cognition, respiratory functions, and quality of life in persons with multiple sclerosis: A quasi-experimental study</strong> <br>Authors: Abasıyanık Z., Yiğit P., ÖZDOĞAR A. T., Kahraman T., ERTEKİN Ö., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Five-year real-world data on fingolimod treatment’s effects on cognitive function</strong> <br>Authors: ÖZAKBAŞ S., Piri Cinar B., Yigit P., Baba C., Sagici O. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression</strong> <br>Authors: De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies</strong> <br>Authors: Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sørensen P. S., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis</strong> <br>Authors: Yigit P., Açıkgöz A., Mehdiyev Z., Dayı A., Özakbaş S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis</strong> <br>Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?</strong> <br>Authors: Sen S., Karabudak R., Schiavetti I., Demir S., Ozakbas S., Tutuncu M., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey</strong> <br>Authors: Uzunkopru C., Tutuncu M., Gunduz T., GÜMÜŞ H., Sen S., Demir S., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Cross-cultural adaptation and psychometric properties of the Turkish version of the Manual Ability Measure-36 (MAM-36) in people with multiple sclerosis</strong> <br>Authors: ERTEKİN Ö., Kahraman T., Aras M., Baba C., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis</strong> <br>Authors: Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Validity and reliability of "Cognitive Reserve Index Questionnaire" for the Turkish Population</strong> <br>Authors: ÖZAKBAŞ S., Yigit P., Akyuz Z., Sagici O., Abasiyanik Z., ÖZDOĞAR A. T., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>High and low efficacy therapy in secondary progressive multiple sclerosis</strong> <br>Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis</strong> <br>Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Cross-cultural adaptation, validity and reliability of the Turkish version of the patient determined disease steps scale in persons with multiple sclerosis</strong> <br>Authors: Kahraman T., ÖZDOĞAR A. T., ÖZAKBAŞ S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Assessment of brain atrophy and lesion burden with clinical outcomes in multiple sclerosis real-world practice: The NeuroSTREAM MSBase retrospective, longitudinal study</strong> <br>Authors: Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis</strong> <br>Authors: Harding-Forrester S., Roos I., Sharmin S., Diouf I., Malpas C., Nguyen A., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Prevalence and determinants of falls in persons with multiple sclerosis without a clinical disability</strong> <br>Authors: Abasiyanik Z., Kahraman T., Ertekin Ö., Baba C., Özakbaş S. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Delay from treatment start to full effect of immunotherapies for multiple sclerosis</strong> <br>Authors: Roos I., Leray E., Frascoli F., Casey R., William Brown J., Horakova D., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts</strong> <br>Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score</strong> <br>Authors: Kunchok A., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al. <br>Citations: Unknown, Year: 2021 </li> <li><strong>Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis</strong> <br>Authors: Minh Le M. L., Malpas C., Sharmin S., H <br>Citations: Unknown, Year: Unknown </li> <li> <strong>Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study</strong><br> Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.<br> Year: 2021 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a</strong><br> Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.<br> Year: 2021 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Balance and Gait Impairment in Persons with Multiple Sclerosis with the Absence of Clinical Disability</strong><br> Ayan H., ERTEKİN Ö., Kahraman T., ÖZAKBAŞ S.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Delay from treatment start to full effect of immunotherapies for multiple sclerosis</strong><br> Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Explanatory factors of balance confidence in persons with multiple sclerosis: Beyond the physical functions</strong><br> Abasiyanik Z., Özdoğar A. T., Sagici O., Kahraman T., Baba C., Ertekin Ö., et al.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Effect of video-based exergaming on arm and cognitive function in persons with multiple sclerosis: A randomized controlled trial</strong><br> ÖZDOĞAR A. T., ERTEKİN Ö., Kahraman T., Yigit P., ÖZAKBAŞ S.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Early clinical markers of aggressive multiple sclerosis</strong><br> Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder</strong><br> Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., et al.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>The effects of Clinical Pilates training on walking, balance, fall risk, respiratory, and cognitive functions in persons with multiple sclerosis: A randomized controlled trial</strong><br> Abasiyanik Z., ERTEKİN Ö., Kahraman T., Yigit P., ÖZAKBAŞ S.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Risk of secondary progressive multiple sclerosis: A longitudinal study</strong><br> Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., et al.<br> Year: 2020 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Determinant Role of Magnetic Resonance Imaging in Transition of Clinical Isolated Syndrome to Multiple Sclerosis</strong><br> PİRİ ÇİNAR B., ÖZ D., BİRCAN KURŞUN B., GÜRKAN M., ÖZTÜRK O., ÖZAKBAŞ S.<br> Year: 2019 | Citation Count/Metrics: Hakemli Dergi </li> <li> <strong>The Determinant Role of Magnetic Resonance Imaging in Conversion from Clinically Isolated Syndrome to Multiple Sclerosis (Klinik İzole Sendromda Multipl Skleroza Dönüşümde Manyetik Rezonans Görüntülemenin Belirleyici Rolü)</strong><br> PİRİ ÇİNAR B., ÖZ D., BİRCAN KURŞUN B., GÜRKAN M. A., ÖZTÜRK O., ÖZAKBAŞ S.<br> Year: 2019 | Citation Count/Metrics: Hakemli Dergi </li> <li> <strong>Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis</strong><br> BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., et al.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Effect of hormonal changes on the neurological status in the menstrual cycle of patient with multiple sclerosis</strong><br> Yorgun Y. G., ÖZAKBAŞ S.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>The multiple sclerosis work difficulties questionnaire: translation and cross-cultural adaptation to Turkish and assessment of validity and reliability</strong><br> Kahraman T., ÖZDOĞAR A. T., Honan C. A., ERTEKİN Ö., ÖZAKBAŞ S.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>The 20-year history: Change of multiple sclerosis patient profile over 20 years</strong><br> ÖZAKBAŞ S., ÇİNAR B. P., Kahraman T.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis</strong><br> ÖZAKBAŞ S., Cinar B. P., Oz D., Kosehasanogullari G., Kursun B. B., Kahraman T.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis</strong><br> Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., et al.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Frequency, type, distribution of pain and related factors in persons with multiple sclerosis'</strong><br> Kahraman T., ÖZDOĞAR A. T., ERTEKİN Ö., ÖZAKBAŞ S.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Cognitive involvement in clinically isolated syndrome and relationship with fatigue</strong><br> ÇİNAR B. P., Yigit P., Gurkan M. A., Ozturk O., ÖZAKBAŞ S.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis</strong><br> Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., et al.<br> Year: 2019 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Effects of cigarette smoking on respiratory problems and functional levels in multiple sclerosis patients</strong><br> Aktan R., ÖZALEVLİ S., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Relationship between Trunk Flexor Muscle Strength and Walking, Balance, and Falls in Multiple Sclerosis Patients (Multipl skleroz hastalarında gövde fleksör kas kuvvetinin yürüme,denge ve düşme ile ilişkis)</strong><br> ABASIYANIK Z., ERTEKİN Ö., KAHRAMAN T., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>Balance and Gait Disorder in Early Stages of Multiple Sclerosis (Multipl sklerozun erken evrelerinde denge ve yürüyüş bozukluğu)</strong><br> AYAN H., ERTEKİN Ö., KAHRAMAN T., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>Frequency, Type, Distribution of Pain and Related Factors in Individuals with Multiple Sclerosis (Multipl sklerozlu bireylerde ağrının sıklığı, tipi, dağılımı ve ağrıyla ilişkili etmenler)</strong><br> KAHRAMAN T., ÖZDOĞAR A. T., ERTEKİN Ö., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>Relationship between Respiratory Muscle Strength and Cognitive Functions in Multiple Sclerosis (Multipl sklerozda solunum kas kuvveti ile kognitif fonksiyonlararasında ilişki)</strong><br> ABASIYANIK Z., ERTEKİN Ö., KAHRAMAN T., YİĞİT P., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>The Effect of Clinical Pilates Training on Balance, Walking, Fall Risk, Respiratory Functions, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalarında klinik Pilates eğitiminin denge, yürüme,düşme riski, solunum fonksiyonları ve kognitif fonksiyonlar üzerineetkisi: randomize kontrollü çalışma)</strong><br> ABASIYANIK Z., ERTEKİN Ö., KAHRAMAN T., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial</strong><br> ÖZAKBAŞ S., Turkoglu R., Tamam Y., TERZİ M., Taskapilioglu O., YÜCESAN C., et al.<br> Year: 2018 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study</strong><br> Cinar B. P., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Smoking is associated with walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis</strong><br> Ozdogar A., Kahraman T., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Long-term test-retest reliability and validity of the Six Spot Step Test in individuals with multiple sclerosis (Altı Nokta Adım Testi’nin multiple sklerozlu bireylerdeki uzun dönem test-tekrar test uyum ve güvenirliliği)</strong><br> ÖZDOĞAR A. T., KAHRAMAN T., ERTEKİN Ö., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>FEASIBILITY OF A 6-MONTH YOGA PROGRAM TO IMPROVE THE PHYSICAL AND PSYCHOSOCIAL STATUS OF PERSONS WITH MULTIPLE SCLEROSIS AND THEIR FAMILY MEMBERS</strong><br> Kahraman T., ÖZDOĞAR A. T., Yigit P., Hosgel I., Mehdiyev Z., ERTEKİN Ö., et al.<br> Year: 2018 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Upper Extremity Dysfunction in Multiple Sclerosis Patients without Clinical Disability (Klinik özürü olmayan Multipl skleroz hastalarında üst ekstremite fonksiyon bozukluğu)</strong><br> ÖZDOĞAR A. T., KAHRAMAN T., ERTEKİN Ö., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>Restless Legs Syndrome and Related Factors in Multiple Sclerosis Patients (Multipl sklerozlu hastalarında huzursuz bacak sendromu ve ilişkili faktörler)</strong><br> ÖZDOĞAR A. T., KAHRAMAN T., YİĞİT P., HOŞGEL İ., ERTEKİN Ö., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>The Effect of Video Game Based Physical Activity Approach on Upper Extremity Function, Walking, Balance, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalarında video oyunlari temelli fiziksel aktivite yaklaşımının üst ekstremite fonksiyonu, yürüme, denge ve kognitif fonksiyonlar üzerine etkisi: randomize kontrollü çalışma)</strong><br> ÖZDOĞAR A. T., ERTEKİN Ö., KAHRAMAN T., YİĞİT P., ÖZAKBAŞ S.<br> Year: 2018 | Citation Count/Metrics: Scopus </li> <li> <strong>The Turkish validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery</strong><br> ÖZAKBAŞ S., Yigit P., Cinar B. P., Limoncu H., Kahraman T., Kosehasanogullari G.<br> Year: 2017 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results</strong><br> ÖZAKBAŞ S., Cinar B. P., KAYA ÖZÇELİK P., Baser H., Kosehasanogullari G.<br> Year: 2017 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial</strong><br> ÖZAKBAŞ S., Cinar B. P., Kosehasanogullari G., Kahraman T., Oz D., Kursun B. B.<br> Year: 2017 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>"No evidence of disease activity - cognition" in relapsing-remitting multiple sclerosis: recommendation for an extensive assessment of disease activity</strong><br> ÖZAKBAŞ S., Cinar B. P., Yigit P., Kosehasanogullari G.<br> Year: 2017 | Citation Count/Metrics: SCI-Expanded </li> <li> <strong>Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery</strong><br> Cinar B. P., Kosehasanogullari G., Yigit P., ÖZAKBAŞ S.<br> Year: 2017 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Social Cognition in Multiple Sclerosis: a Meta-Analysis</strong><br> BORA İ. E., ÖZAKBAŞ S., Velakoulis D., Walterfang M.<br> Year: 2016 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Utilization of the Expanded Disability Status Scale as a distinctive instrument for walking impairment in persons with multiple sclerosis with mild disability</strong><br> Kahraman T., SAVCI S., Poyraz E. C., ÖZAKBAŞ S., Idiman E.<br> Year: 2016 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Paced auditory serial addition test: National normative data</strong><br> ÖZAKBAŞ S., Cinar B. P., Gurkan M. A., Ozturk O., Oz D., Kursun B. B.<br> Year: 2016 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Reassessment of Lhermitte’s sign in multiple sclerosis</strong><br> BECKMANN Y., ÖZAKBAŞ S., Bulbul N. G., Kosehasanogullari G., SEÇİL Y., Bulut O., et al.<br> Year: 2015 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Cognitive Impairment in Multiple Sclerosis: Historical Aspects, Current Status, and Beyond</strong><br> ÖZAKBAŞ S.<br> Year: 2015 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Determinants of physical activity in minimally impaired people with multiple sclerosis</strong><br> Kahraman T., SAVCI S., Coskuner-Poyraz E., ÖZAKBAŞ S., Idiman E.<br> Year: 2015 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too</strong><br> Kosehasanogullari G., ÖZAKBAŞ S., Idiman E.<br> Year: 2015 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Uveitis associated with multiple sclerosis: complications and visual prognosis</strong><br> Kaya D., KAYA M., ÖZAKBAŞ S., Idiman E.<br> Year: 2014 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Contingent Negative Variation Is Associated with Cognitive Dysfunction and Secondary Progressive Disease Course in Multiple Sclerosis</strong><br> UYSAL U., Idiman F., Idiman E., ÖZAKBAŞ S., Karakas S., Bruce J.<br> Year: 2014 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Early Deterioration In Quality Of Life And Physical Functioning Of Multiple Sclerosis Patients</strong><br> ERTEKİN Ö., ÖZAKBAŞ S., İDİMAN E.<br> Year: 2014 | Citation Count/Metrics: Hakemli Dergi </li> <li> <strong>Caregiver burden, quality of life and walking ability in different disability levels of multiple sclerosis.</strong><br> Ertekin Ö., ÖZAKBAŞ S., Idiman E.<br> Year: 2014 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: Comparison of the results with that of multiple sclerosis patients</strong><br> Cinar B. P., ÖZAKBAŞ S., Idiman E.<br> Year: 2013 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Importance of neutralizing antibody positivity in Turkish multiple sclerosis patients</strong><br> KAYA D., TUFAN S., ÖZAKBAŞ S., BAHAR H., ADA E., İDİMAN E.<br> Year: 2013 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Sexual dysfunction in multiple sclerosis: Gender differences</strong><br> Celik D. B., Poyraz E. C., Bingol A., Idiman E., ÖZAKBAŞ S., Kaya D.<br> Year: 2013 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>The Comparison of Physical Activity Status, Exercise Perception and Quality of Life Between Clinically Isolated Syndrome and Multiple Sclerosis Patients</strong><br> Ertekin Ö., ÖZAKBAŞ S., Cinar B. P., ALGUN Z. C., Idiman E.<br> Year: 2013 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>The Effects of Low and Severe Disability on Walking Abilities and Quality of Life in Multiple Sclerosis Patients: 6-Month Follow-up Study</strong><br> Ertekin Ö., ÖZAKBAŞ S., Idiman E., ALGUN Z. C.<br> Year: 2013 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Early onset multiple sclerosis has worse prognosis than adult onset multiple sclerosis based on cognition and magnetic resonance imaging</strong><br> ÖZAKBAŞ S., KAYA D., Idiman E.<br> Year: 2012 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Inflammatory demyelinating central nervous system diseases in childhood: Clinical and paraclinical profiles in 133 patients</strong><br> Kaya D., Idiman E., ÖZAKBAŞ S.<br> Year: 2012 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Quality of Life, Fatigue and Balance Improvements after Home-Based Exercise Program in Multiple Sclerosis Patients</strong><br> ERTEKİN Ö., ÖZAKBAŞ S., Idiman E., ALGUN Z. C.<br> Year: 2012 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Symptomatic Menagement in Multiple Sclerosis</strong><br> Ozakbas S.<br> Year: 2011 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis</strong><br> Idiman E., ÖZAKBAŞ S.<br> Year: 2011 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Effect of cognitive function and physical activity on the ability to learn and reproduce physiotherapy exercises in healthy subjects</strong><br> Kara B., GENÇ A., Colakoglu B. D., ÖZAKBAŞ S.<br> Year: 2011 | Citation Count/Metrics: SCI-Expanded </li> <li> <strong>A Case of Fever of Unknown Origin: Co-existence of Kikuchi-Fujimoto Disease and Acute Disseminated Encephalomyelitis (ADEM)</strong><br> AVKAN OĞUZ V., Yapar N., ÖZAKBAŞ S., Demir-Onder K., Aktas E., ALP ÇAVUŞ S., et al.<br> Year: 2010 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>The significance of oligoclonal bands in multiple sclerosis: Relevance of demographic and clinical features, and immunogenetic backgrounds</strong><br> Idiman E., Özakbaş S., Doğan Y., Kosehasanogullari G.<br> Year: 2009 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy</strong><br> Ozakbas S., Akdede B. B., Kosehasanogullari G., Aksan O., Idiman E.<br> Year: 2007 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes</strong><br> Ozakbas S., Idiman E., Yulug B., Pakoz B., Bahar H., Gulay Z.<br> Year: 2006 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in Multiple Sclerosis patients</strong><br> Yozbatiran N., Baskurt F., Baskurt Z., Ozakbas S., Idiman E.<br> Year: 2006 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample</strong><br> Idiman E., Uzunel F., Ozakbas S., Yozbatiran N., Oguz M., Callioglu B., et al.<br> Year: 2006 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies</strong><br> Ozakbas S., Ormeci B., Idiman E.<br> Year: 2005 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Intrathecal sICAM-1 production in multiple sclerosis - Correlation with triple dose Gd-DTPA MRI enhancement and IgG index</strong><br> Acar G., Idiman F., Kirkali G., Ozakbas S., Oktay G., Cakmakci H., et al.<br> Year: 2005 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Visual evoked potential is superior to triple dose magnetic resonance imaging in the diagnosis of optic nerve involvement</strong><br> Acar G., Ozakbas S., Cakmakci H., Idiman F., Idiman E.<br> Year: 2004 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features</strong><br> Donmez B., Ozakbas S., Oktem M., Gedizlioglu M., Coker I., Genc A. A., et al.<br> Year: 2004 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis</strong><br> Ozakbas S., Cagiran I., Ormeci B., Idiman E.<br> Year: 2004 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Utilization of the auditory consonant trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the paced auditory serial addition test</strong><br> Ozakbas S., Ormeci B., Akdede B. B., ALPTEKİN K., Idiman E.<br> Year: 2004 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features</strong><br> Ozakbas S., Idiman E., Baklan B., Yulug B.<br> Year: 2003 | Citation Count/Metrics: PlumX Metrics </li> <li> <strong>Nitric oxide as an activity marker in multiple sclerosis</strong><br> Acar G., Idiman F., Idiman E., Kirkali G., Cakmakci H., Ozakbas S.<br> Year: 2003 | Citation Count/Metrics: PlumX Metrics </li> </ul>